They are also referred to as “corporate earnings” and “corporate profits:” basically, the amount of money a company makes in certain period of time. The price/earnings multiple is still the most common tool used to value a company. The stock market values a company based on the amount of money—the earnings and profits—the company has after all expenses, including taxes, have been paid. In a stock market where stocks are traded at an average of 12 times earnings, a company making $1.00 a share per year would be valued at $12.00. All things being equal, the more money a public company makes, the higher its stock price.
As corporate earnings tumble in, equity market action has been more tuned to stronger oil prices. A number of companies have now reported, and the numbers aren’t that bad. It’s still in the early stages, of course, but so far, there have been a lot of good financials. Having said that, sales growth has been missing early this corporate earnings season…. Read More
First-quarter earnings season is on the horizon and early reporters, so far, are revealing the same results we got in 4Q14—a decent bottom line, but sales coming up short. So far, my early 1Q15 earnings forecast predicts a boring reporting season.
Oracle Among Companies Keeping Investor Interest with Dividend Boosts
Several important benchmark companies report just before the calendar quarter closes…. Read More
Looking ahead to 2015, the first and most obvious news the marketplace will be looking for is fourth-quarter earnings.
Even before oil prices experienced their material sell-off, fourth-quarter earnings were looking good, as corporate reporting in both the second and third quarters of 2014 estimated a solid finish to the year.
Now that oil prices are lower, they’re likely going to pad earnings for a number of industries in 2015…. Read More
Earnings season continues and the deluge of results is positively affecting the S&P 500, which is pushing new record highs.
Also continuing its positive upward trend are biotechnology stocks, which still harbor a lot of price momentum from institutional investors.
Ligand Pharmaceuticals Incorporated (LGND) has been very hot since the beginning of the year…. Read More
There is a huge amount of news for the stock market to digest this week, with both economic data and company earnings reports. The stock market has been unsure of itself the last couple of weeks, wondering if the rally off of the Federal Reserve’s third round of quantitative easing (QE3) was a fake out. Now, the market needs company earnings in order to justify its current level; the only problem being, they aren’t expected to grow much over last year’s third quarter…. Read More